ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,104Medicare Part D Prescriptions Filled, Including Refills

Rank: 57 out of 198

$517K Total Retail Price of All Prescriptions

Rank: 55 out of 198

383 Patients Receiving at Least One Drug in Part D
81%Patients 65 Years and Older
36% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 383 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

18% of this provider’s 383 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

2% of this provider’s 7,968 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$51 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
LEVOTHYROXINE SODIUM 747 600 1 1
OMEPRAZOLE 359 254 2 3
HYDROCODONE-ACETAMINOPHEN 326 208 S3 3 8
WARFARIN SODIUM 280 237 4 7
LISINOPRIL 225 179 5 6
FUROSEMIDE 220 185 6 5
SIMVASTATIN 212 186 7 2
AMLODIPINE BESYLATE 178 173 8 4
TRAMADOL HCL 166 104 9 15
POTASSIUM CHLORIDE 166 144 9 9
CITALOPRAM HBR 155 123 11 20
LISINOPRIL-HYDROCHLOROTHIAZIDE 151 138 12 38
DONEPEZIL HCL 131 131 13 28
CARVEDILOL 131 114 13 24
ATORVASTATIN CALCIUM 125 108 15 12
ESCITALOPRAM OXALATE 125 117 15 53
ATENOLOL 121 121 17 17
CRESTOR 121 86 17 26
PREDNISONE 118 95 19 29
LOSARTAN POTASSIUM 115 99 20 18
GABAPENTIN 115 74 20 14
METOPROLOL SUCCINATE 114 91 22 11
SPIRONOLACTONE 110 85 23 37
MIRTAZAPINE 104 103 24 44
METFORMIN HCL 98 64 25 13
ALENDRONATE SODIUM 97 90 26 21
RANITIDINE HCL 95 78 27 54
METOPROLOL TARTRATE 82 76 28 10
BYSTOLIC 78 65 29 58
NAMENDA 77 77 30 33
MELOXICAM 74 58 31 30
METFORMIN HCL ER 70 66 32 64
HYDROCHLOROTHIAZIDE 65 58 33 16
LEVOFLOXACIN 64 50 34 81
SINGULAIR 63 40 35 106
LIOTHYRONINE SODIUM 62 57 36 260
CYCLOBENZAPRINE HCL 62 43 R 36 67
SYNTHROID 62 46 36 36
LOVASTATIN 61 51 39 70
AZITHROMYCIN 61 42 39 56
GLIPIZIDE 61 38 39 62
QUETIAPINE FUMARATE 60 48 42 76
ZOLPIDEM TARTRATE 58 48 43 22
CYMBALTA 54 26 44 48
CLONIDINE HCL 54 50 44 52
FLUTICASONE PROPIONATE 53 39 46 39
ALLOPURINOL 53 53 46 23
TAMSULOSIN HCL 51 44 48 27
NYSTATIN 51 46 48 148
SERTRALINE HCL 51 33 48 25
JANUVIA 50 28 51 86
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 29, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.